Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2021-08-23 Board/Management Inform…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical hires Patrick Jamnik to head US business
Board/Management Information Classification · 1% confidence The document announces the hiring of a new executive, Patrick Jamnik, to head the US business operations. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The text focuses entirely on the new hire's background, role, and quotes from management regarding the appointment. It is not a financial report, earnings release, or regulatory filing like a 10-K or IR.
2021-08-23 English
European multicentre study initiated for 5 years’ follow-up of Episealer® Talus patients
Regulatory Filings Classification · 1% confidence The document is a short announcement from Episurf Medical regarding the initiation of a European multicentre study for their Episealer® Talus product, including details about follow-up periods and interim results. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, management discussion, or proxy statement. It is a specific operational/clinical update. Since it doesn't fit the specific categories like DIRS, DIV, CAP, or ER, and it is a general announcement about company activity that is not a standard regulatory filing like a 10-K, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or significant operational announcements that don't match other specific types. Given the length (2565 chars) and content, it is an announcement, not a full report.
2021-07-22 English
Europeisk multicenterstudie med 5-årsuppföljning av Episealer® Talus-patienter initierad
Regulatory Filings Classification · 1% confidence The document announces the initiation of a prospective, investigator-initiated European multicenter study for Episealer® Talus patients, detailing the follow-up period (5 years), measurement instruments (VAS, FAOS, EQ-5D-5L), and planned interim results submission. It includes quotes from key personnel and concludes with a statement that the information is disclosed pursuant to the EU Market Abuse Regulation (MAR) and was released at a specific time (08:45 on July 22, 2021). This type of announcement, detailing clinical trial progress or significant operational/research updates that are not standard financial reports (10-K, IR, ER), typically falls under general regulatory announcements or investor relations updates. Since it is not a specific financial report, management change, dividend notice, or transaction report, and it is a formal disclosure required by regulation, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially 'LTR' if it were about legal proceedings, but here it is about a clinical study initiation. Given the context of MAR disclosure, RNS is the most appropriate general regulatory catch-all for non-standard disclosures.
2021-07-22 Swedish
Episealer® Talus: Fallstudie med 5-års uppföljningsdata accepterad för publicering
Regulatory Filings Classification · 1% confidence The document announces that a case study ('fallstudie'/'Case report') regarding the Episealer® Talus implant with 5-year follow-up data has been accepted for publication in the peer-reviewed journal 'Foot & Ankle Surgery: Techniques, Reports & Cases'. It details the content of the study, quotes an advisor, and concludes with boilerplate information and a statement that the information is being made public under EU market abuse regulation. Since this is an announcement about the acceptance and impending publication of a scientific/clinical report, and not the full report itself, it fits best under the category for general regulatory announcements or news releases that don't fit specific financial reporting codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release announcing scientific/clinical news, as it is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance filing. The document length (3921 chars) is short, suggesting it is an announcement rather than the full scientific paper.
2021-07-16 Swedish
Episealer® Talus: Case report with 5-years’ follow-up data accepted for publication
Legal Proceedings Report Classification · 1% confidence The document is a short announcement from Episurf Medical stating that a case report detailing 5-years' follow-up data for their Episealer® Talus implant has been 'accepted for publication' in a scientific journal. It provides details about the case, the authors, and the expected publication date. Crucially, the document itself is not the full scientific report, nor is it a standard regulatory filing like a 10-K or ER. Since it is an announcement about the publication of specific information (a case report), and it doesn't fit neatly into the other specific categories (like DIV, DIRS, or MANG), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements, or potentially 'LTR' if viewed as reporting on a specific medical/legal outcome, but RNS is more appropriate for general publication notices that aren't core financial reports. Given the context of reporting on a specific medical finding/case study, LTR (Legal Proceedings Report) is a possibility if the case report is viewed as a report on a specific medical outcome/test, but RNS is the safest general regulatory announcement fallback. However, since it is an announcement about a scientific publication, and not a standard financial or governance filing, RNS is the most suitable general category.
2021-07-16 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Kvartalsrapport 1 april – 30 juni 2021' (Quarterly Report April 1 – June 30, 2021). It contains comprehensive financial statements, including income statements, balance sheet data, management commentary, and analysis of business performance for the second quarter and first half of 2021. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. Q2 2021
2021-07-16 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.